Cardiovascular side effects and the early use of ADT — another large data set analysis

A newly published paper in BJU International has expanded our understanding of the cardiovascular risks associated with the use of androgen deprivation therapy (ADT) — most particularly in older men treated with ADT as their first-line form of therapy. … READ MORE …

Is treatment with degarelix really “better” than treatment with an LHRH agonist? Part II

Yesterday we commented (by request) on a paper by Klotz et al. suggesting that initial treatment with the LHRH antagonist degarelix might have benefits compared to initial treatment with an LHRH agonist such as leuprolide or goserelin acetate. … READ MORE …

Can the new hormone therapies actually replace the older ones?

Here is a question that is on the minds of many physicians and patients on Planet Prostate Cancer today: Can treatment with abiraterone acetate or similar agents replace the continuous and/or the intermittent first-line use of LHRH-agonist–induced medical castration in patients with high-risk and advanced forms of prostate cancer? … READ MORE …

Recovery of serum T levels after short-term LHRH agonist therapy

An article in the June issue of the Canadian Urological Association Journal offers preliminary evidence from a randomized clinical trial that men treated for 6 months with a short-acting LHRH agonist may recover normal serum testosterone (T) levels faster than those treated for the same time with a long-acting LHRH agonist. … READ MORE …

Does switching LHRH agonists have a real clinical benefit?

There are two potentially good reasons for a patient who is receiving treatment with an LHRH agonist to switch from one product to another: the first is because he is having a problem with the adverse effects of his initial LHRH therapy; the second is because he has a rising PSA on the initial LHRH agonist. … READ MORE …

Colorectal cancer among prostate cancer patients treated with ADT

As if it wasn’t long enough already, the list of adverse events “associated with” the use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is growing. … READ MORE …

Changes in use of LHRH agonists between 2003 and 2005 and related matters

Financial disincentives related to prescribing of LHRH agonists introduced in 2003 have clearly been associated with changes in actual physician prescriptions for drugs like Lupron and Zoladex in the immediately following years. … READ MORE …